BACKGROUND: Although myocardial interstitial fibrosis has been considered to play a pathogenic role in chronic heart failure (HF), the role of perivascular fibrosis, another form of fibrosis, remains to be elucidated. METHODS: We examined 64 consecutive patients with non-ischemic HF caused by hypertrophic cardiomyopathy (HCM, n=16), hypertensive heart disease (HHD, n=11), or dilated cardiomyopathy (DCM, n=37), diagnosed by both cardiac catheterization and endomyocardial biopsy (right ventricular side of the interventricular septum) in the Tohoku University Hospital between January 2001 and April 2009. We calculated the collagen volume fraction (CVF) and perivascular fibrosis ratio (PFR) in biopsy samples and also examined Thrombolysis in Myocardial Infarction (TIMI) frame count to evaluate coronary blood flow. RESULTS: There was no significant correlation between CVF and PFR (r(2)=0.0007). Although CVF was comparable among HCM, HHD, and DCM (1.11 ± 1.04, 1.89 ± 1.61, and 1.41 ± 1.48, respectively), PFR was significantly higher in HCM than in DCM (1.78 ± 1.09 vs. 1.23 ± 0.44, p<0.05). PFR was not correlated with cardiac function parameters, such as left ventricular (LV) ejection fraction, cardiac output, LV end-diastolic pressure, LV end-diastolic volume, aortic pressure, or pulmonary artery pressure. However, PFR was significantly correlated with coronary flow in the left anterior descending coronary artery (as evaluated by TIMI frame count) (r(2)=0.3351, p<0.0001, in all-cases combined population), but not with that in the left circumflex or right coronary artery. This correlation remained significant in a logistic regression model tested in 7 variables (body mass index, PVR, CVF, presence of hypertension, dyslipidemia, diabetes mellitus, and atrial fibrillation). CONCLUSIONS: These results indicate that coronary perivascular fibrosis is associated with the impairment of coronary blood flow although not associated with interstitial fibrosis or cardiac function, suggesting that it can be a new therapeutic target to improve coronary microcirculation.
BACKGROUND: Although myocardial interstitial fibrosis has been considered to play a pathogenic role in chronic heart failure (HF), the role of perivascular fibrosis, another form of fibrosis, remains to be elucidated. METHODS: We examined 64 consecutive patients with non-ischemic HF caused by hypertrophic cardiomyopathy (HCM, n=16), hypertensive heart disease (HHD, n=11), or dilated cardiomyopathy (DCM, n=37), diagnosed by both cardiac catheterization and endomyocardial biopsy (right ventricular side of the interventricular septum) in the Tohoku University Hospital between January 2001 and April 2009. We calculated the collagen volume fraction (CVF) and perivascular fibrosis ratio (PFR) in biopsy samples and also examined Thrombolysis in Myocardial Infarction (TIMI) frame count to evaluate coronary blood flow. RESULTS: There was no significant correlation between CVF and PFR (r(2)=0.0007). Although CVF was comparable among HCM, HHD, and DCM (1.11 ± 1.04, 1.89 ± 1.61, and 1.41 ± 1.48, respectively), PFR was significantly higher in HCM than in DCM (1.78 ± 1.09 vs. 1.23 ± 0.44, p<0.05). PFR was not correlated with cardiac function parameters, such as left ventricular (LV) ejection fraction, cardiac output, LV end-diastolic pressure, LV end-diastolic volume, aortic pressure, or pulmonary artery pressure. However, PFR was significantly correlated with coronary flow in the left anterior descending coronary artery (as evaluated by TIMI frame count) (r(2)=0.3351, p<0.0001, in all-cases combined population), but not with that in the left circumflex or right coronary artery. This correlation remained significant in a logistic regression model tested in 7 variables (body mass index, PVR, CVF, presence of hypertension, dyslipidemia, diabetes mellitus, and atrial fibrillation). CONCLUSIONS: These results indicate that coronary perivascular fibrosis is associated with the impairment of coronary blood flow although not associated with interstitial fibrosis or cardiac function, suggesting that it can be a new therapeutic target to improve coronary microcirculation.
Authors: Volodymyr V Balatskyi; Larysa L Macewicz; Ana-Maria Gan; Sergii V Goncharov; Paulina Pawelec; Georgiy V Portnichenko; Tetiana Yu Lapikova-Bryginska; Viktor O Navrulin; Victor E Dosenko; Adam Olichwier; Pawel Dobrzyn; Oksana O Piven Journal: Pflugers Arch Date: 2018-06-20 Impact factor: 3.657
Authors: Cini Mathew John; Rayan Khaddaj Mallat; Ramesh C Mishra; Grace George; Vikrant Singh; Jeannine D Turnbull; Channakeshava S Umeshappa; Dylan J Kendrick; Taeyeob Kim; Fazlin M Fauzi; Frank Visser; Paul W M Fedak; Heike Wulff; Andrew P Braun Journal: Pharmacol Res Date: 2019-11-07 Impact factor: 7.658
Authors: Jessica C Garbern; Jason Williams; Amy C Kristl; Alyyah Malick; Inbal Rachmin; Benjamin Gaeta; Nafis Ahmed; Ana Vujic; Peter Libby; Richard T Lee Journal: J Mol Cell Cardiol Date: 2019-02-11 Impact factor: 5.000
Authors: Niranjana Natarajan; Ana Vujic; Jishnu Das; Annie C Wang; Krystal K Phu; Spencer H Kiehm; Elisabeth M Ricci-Blair; Anthony Y Zhu; Kelli L Vaughan; Ricki J Colman; Julie A Mattison; Richard T Lee Journal: JCI Insight Date: 2019-09-19
Authors: Bastiaan J van Nierop; Bram F Coolen; Noortje A Bax; Wouter J R Dijk; Elza D van Deel; Dirk J Duncker; Klaas Nicolay; Gustav J Strijkers Journal: Int J Cardiovasc Imaging Date: 2014-01-28 Impact factor: 2.357
Authors: Nicholas Ieronimakis; Aislinn L Hays; Kajohnkiart Janebodin; William M Mahoney; Jeremy S Duffield; Mark W Majesky; Morayma Reyes Journal: J Mol Cell Cardiol Date: 2013-08-01 Impact factor: 5.000
Authors: Rachel N Andrews; David L Caudell; Linda J Metheny-Barlow; Ann M Peiffer; Janet A Tooze; J Daniel Bourland; Robert E Hampson; Samuel A Deadwyler; J Mark Cline Journal: Radiat Res Date: 2018-07-17 Impact factor: 2.841